Income Statement Location [Axis]
Research and Development [Member]
General and Administrative [Member]
Award Type [Axis]
Restricted Stock Units (RSUs) [Member]
Related Party [Axis]
KCM [Member]
Investment [Axis]
Certificates of Deposit [Member]
Domestic Governmental Agency Loans [Member]
U.S Treasury Notes [Member]
Range [Axis]
Minimum [Member]
Maximum [Member]
Employee Stock Awards [Member]
Equity Components [Axis]
Preferred Stock [Member]
Common Stock [Member]
Additional Paid-In Capital [Member]
Treasury Stock [Member]
Accumulated Deficit [Member]
Type of Arrangement and Non-arrangement Transactions [Axis]
Aratana Agreement [Member]
Antidilutive Securities [Axis]
Warrants [Member]
Stock Options [Member]
Plan Name [Axis]
2011 Employee Stock Purchase Plan [Member]
2015 Plan [Member]
Scenario [Axis]
Stock Split [Member]
Additional Shares [Member]
Derivative Instrument [Axis]
Exercise Price Range $0.60 - $4.99 [Member]
Exercise Price Range $5.00 - $9.99 [Member]
Exercise Price Range $10.00 - $14.99 [Member]
Exercise Price Range $15.00 - $21.25 [Member]
Amgen Agreement [Member]
Stendhal Agreement [Member]
Business Acquisition [Axis]
MedImmune Agreement [Member]
Debt Instrument [Axis]
Global BioPharma, Inc [Member]
401(k) Plan [Member]
Director Stock Awards [Member]
Title of Individual [Axis]
Consultants [Member]
Merck Agreement [Member]
Lease Arrangement, Type [Axis]
Corporate Office & Manufacturing Facility Lease [Member]
Restricted Stock Units [Member]
Underwriting Agreement [Member]
Sale of Stock [Axis]
IPO [Member]
Creation Date [Axis]
October 2013 Through October 2018 [Member]
December 31, 2018 [Member]
Especificos Stendhal SA de CV [Member]
Income Tax Authority, Name [Axis]
Internal Revenue Code [Member]
Subsequent Event Type [Axis]
Subsequent Event [Member]
Executives [Member]
Non Executive Directors [Member]
Employee Stock Purchase Plan [Member]
2015 Employee Stock Purchase Plan [Member]
Warrant Liability [Member]
Fair Value Hierarchy and NAV [Axis]
Fair Value, Inputs, Level 1 [Member]
Fair Value, Hierarchy [Axis]
Fair Value, Inputs, Level 2 [Member]
Fair Value, Inputs, Level 3 [Member]
Document And Entity Information
Entity Registrant Name
Entity Central Index Key
Document Type
Document Period End Date
Amendment Flag
Current Fiscal Year End Date
Entity Well-known Seasoned Issuer
Entity Voluntary Filers
Entity Current Reporting Status
Entity Filer Category
Entity Small Business Flag
Entity Emerging Growth Company
Entity Ex Transition Period
Entity Shell Company
Entity Public Float
Entity Common Stock, Shares Outstanding
Trading Symbol
Document Fiscal Period Focus
Document Fiscal Year Focus
Statement of Financial Position [Abstract]
ASSETS
Current assets:
Cash and cash equivalents
Restricted cash
Short-term investment securities
Income tax receivable
Deferred expenses
Prepaid expenses and other current assets
Total current assets
Property and equipment (net of accumulated depreciation)
Intangible assets (net of accumulated amortization)
Other assets
Total assets
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Accounts payable
Accrued expenses
Deferred revenue
Common stock warrant liability
Other current liabilities
Total current liabilities
Deferred revenue
Other liabilities
Total liabilities
Commitments and contingencies - Note 10
Shareholders' equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; Series B Preferred Stock; 0 shares issued and outstanding at October 31, 2018 and 2017. Liquidation preference of $0 at October 31, 2018 and 2017.
Common stock - $0.001 par value; 95,000,000 shares authorized, 69,556,452 shares issued and outstanding at October 31, 2018 and 41,206,538 shares issued and outstanding at October 31, 2017.
Additional paid-in capital
Accumulated deficit
Total shareholders' equity
Total liabilities and shareholders' equity
Preferred stock, par value
Preferred stock, shares authorized
Series B Preferred stock, shares issued
Series B Preferred stock, shares outstanding
Preferred stock, liquidation preference value
Common stock, par value
Common stock, shares authorized
Common stock, shares issued
Common stock, shares outstanding
Income Statement [Abstract]
Revenue
Operating expenses:
Research and development expenses
General and administrative expenses
Total operating expenses
Loss from operations
Other income (expense):
Interest income
Net changes in fair value of derivative liabilities
Other expense
Net loss before income tax benefit
Income tax expense (benefit)
Net loss
Net loss per common share, basic and diluted
Weighted average number of common shares outstanding, basic and diluted
Statement [Table]
Statement [Line Items]
Balance
Balance, shares
Stock based compensation
Stock based compensation, shares
Tax withholdings paid related to net share settlement of equity awards
Tax withholdings paid on equity awards
Tax withholdings paid on equity awards, shares
Tax shares sold to pay for tax withholdings on equity awards
Tax shares sold to pay for tax withholdings on equity awards, shares
Common Stock issued upon exercise of warrants
Common Stock issued upon exercise of warrants, shares
Issuance of shares to employees under ESPP Plan
Issuance of shares to employees under ESPP Plan, shares
Advaxis at-the-market sales
Advaxis at-the-market sales, shares
Advaxis Public Offering
Advaxis Public Offering, shares
Net Loss
Balance
Balance, shares
Statement of Cash Flows [Abstract]
OPERATING ACTIVITIES
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Stock compensation
Employee stock purchase plan expense
Gain on change in value of warrants
Loss on disposal of property and equipment
Write-off of intangible assets
Depreciation expense
Amortization expense of intangible assets
Net (accretion) amortization of premiums and discounts
Change in operating assets and liabilities:
Prepaid expenses and other current assets
Income taxes receivable
Other assets
Accounts payable and accrued expenses
Deferred revenue
Other liabilities
Net cash used in operating activities
INVESTING ACTIVITIES
Restricted cash established with letter of credit agreement
Purchases of investments
Proceeds from maturities of short-term investment securities
Purchase of property and equipment
Cost of intangible assets
Net cash provided by (used in) investing activities
FINANCING ACTIVITIES
Net proceeds of issuance of common stock and warrants
Proceeds from the exercise of warrants
Proceeds from employee stock purchase plan
Tax withholdings paid related to net share settlement of equity awards
Employee tax withholdings paid on equity awards
Tax shares sold to pay for employee tax withholdings on equity awards
Net cash provided by financing activities
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents at beginning of year
Cash and cash equivalents at end of year
Supplemental Disclosures of Cash Flow Information
Cash paid for taxes
Supplemental Schedule of Noncash Investing and Financing Activities
Accounts payable and accrued expenses settled with common stock
Property and equipment included in accounts payable and accrued expenses
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations and Basis of Presentation
Accounting Policies [Abstract]
Summary of Significant Accounting Policies
Schedule of Investments [Abstract]
Investments
Property, Plant and Equipment [Abstract]
Property and Equipment
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets
Payables and Accruals [Abstract]
Accrued Expenses
Common Stock Purchase Warrants And Warrant Liability
Common Stock Purchase Warrants and Warrant Liability
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share Based Compensation
Collaboration And Licensing Agreements
Collaboration and Licensing Agreements
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies
Income Tax Disclosure [Abstract]
Income Taxes
Equity [Abstract]
Shareholders' Equity
Fair Value Disclosures [Abstract]
Fair Value
Compensation Related Costs [Abstract]
Employee Benefit Plan
Subsequent Events [Abstract]
Subsequent Events
Estimates
Reclassification
Collaboration Agreements
Revenue Recognition
Cash and Cash Equivalents
Concentration of Credit Risk
Restricted Cash and Letter of Credit
Investments
Deferred Expenses
Property and Equipment
Intangible Assets
Impairment of Long-Lived Assets
Net Income (Loss) Per Share
Research and Development Expenses
Stock Based Compensation
Treasury Stock
Fair Value of Financial Instruments
Derivative Financial Instruments
Income Taxes
Recent Accounting Standards
Recently Adopted Accounting Standards
Schedule of Common Stock Excluded from Diluted Net Loss Per Share
Schedule of Investment Securities at Amortized
Schedule of Property and Equipment
Summary of Intangible Assets
Schedule of Amortization Expense
Schedule of Accrued Expenses
Schedule of Warrants Activity
Schedule of Assumptions Used in Warrant Liability
Summary of Share Based Compensation Expense
Summary of RSU Activity and Related Information
Summary of Changes in Stock Option Plan
Summary of Outstanding and Exercisable Options
Summary of Fair Value of Stock Options Granted of BSM
Summary of Future Minimum Payments of Operating Leases
Components of Income Tax Provision (Benefit)
Schedule of Deferred Tax Assets (Liabilities)
Reconciliation Expected Tax (Expense) Benefit Based on Statutory Rate with Actual Tax Expense Benefit
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis
Schedule of Changes in the Fair Value of Warrant Liabilities
Report Date [Axis]
Proceeds from public offering
Cash, restricted cash, cash equivalents
Concentration of credit risk
Estimated useful lives of property and equipment
Estimated useful life of intangible assets
Lease term
Number of common stock excluded from diluted net loss per share
Investments maturity description
Amortized Cost, as Adjusted
Gross Unrealized Holding Gains
Gross Unrealized Holding Losses
Estimated Fair Value
Laboratory equipment, disposed
Leasehold improvements
Laboratory equipment
Furniture and fixtures
Computer equipment
Construction in progress
Total property and equipment
Accumulated depreciation and amortization
Net property and equipment
Finite lived patents expirations year
Book value patent applications, net
Intangible asset amortization expense
Patents
License
Software
Total intangibles
Accumulated amortization
Net intangible assets
2019
2020
2021
2022
2023
Thereafter
Total
Salaries and other compensation
Vendors
Professional fees
Total accrued expenses
Number of warrants issued
Warrants issued
Exercise price of warrants
Warrant term
Number of warrant issued, value
Exercise price
Stock price
Expected term
Volatility percentage
Risk free interest rate
Fair value of the warrant liability
Change in fair value of warrant liability
Common Stock Purchase Warrants And Warrant Liability - Schedule Of Warrants Activity
Number of Warrants, Outstanding, Beginning balance
Number of Warrants, Issued
Number of Warrants, Exercised
Number of Warrants, Expired
Number of Warrants, Outstanding, Ending balance
Weighted-Average Exercise Price, Outstanding, Beginning
Weighted-Average Exercise Price, Issued
Weighted-Average Exercise Price, Exercised
Weighted-Average Exercise Price, Expired
Weighted-Average Exercise Price, Outstanding, Ending
Weighted Average Remaining Contractual Life In Years, Beginning
Weighted Average Remaining Contractual Life In Years, Ending
Aggregate Intrinsic Value, Beginning
Aggregate Intrinsic Value, Ending
Exercise Price
Stock Price
Expected Term
Volatility %
Risk Free Rate
Issuance of common stock
Common stock authorized for issuance
Shares of common stock outstanding, percentage
Common stock reserved for issuance under plan
Fair value of equity purchases value
Unrecognized compensation cost related to non-vested stock option awards
Unrecognized compensation cost related to non-vested remaining weighted average vesting period
Options outstanding, intrinsic value
Share-based compensation, common stock, shares
Share-based compensation, shares on net basis after employee payroll taxes
Share-based compensation, common stock, value
Stock compensation expense
Expected dividend yield
Stock option vested expiration date
Compensation cost related to outstanding stock options
Number of stock shares issued during period amount
Number of options, granted
Fair value of option granted
Stock issued during period for services
Stock issued during period value for services
Common stock shares issued
Employee stock purchase plan description
Discount price percentage
Share-based compensation expense
Number of RSUs, Beginning Balance
Number of RSUs Granted
Number of RSUs Vested
Number of RSUs Cancelled
Number of RSUs, Ending Balance
Weighted-Average Grant Date Fair Value, Outstanding, Beginning
Weighted-Average Grant Date Fair Value, Granted
Weighted-Average Grant Date Fair Value, Vested
Weighted-Average Grant Date Fair Value, Cancelled
Weighted-Average Grant Date Fair Value, Outstanding, Ending
Number of Options, Beginning Balance
Number of Options, Granted
Number of Options, Canceled or Expired
Number of Options, Ending Balance
Number of Options, Vested and Exercisable
Weighted-Average Exercise Price, Outstanding, Beginning
Weighted-Average Exercise Price, Granted
Weighted-Average Exercise Price, Canceled or Expired
Weighted-Average Exercise Price, Outstanding, Ending
Weighted-Average Exercise Price, Vested and Exercisable
Weighted-Average Remaining Contractual Life In Years, Beginning
Weighted-Average Remaining Contractual Life In Years, Ending
Weighted-Average Remaining Contractual Life In Years, Vested and Exercisable
Aggregate Intrinsic Value, Beginning
Aggregate Intrinsic Value, Ending
Aggregate Intrinsic Value, Vested and Exercisable
Range, lower limit
Range, upper limit
Options Outstanding, Number Outstanding
Options Weighted Average Remaining Contractual Term
Options Outstanding, Weighted Average Exercise Price
Options Outstanding, Intrinsic Value
Options Exercisable, Number Outstanding
Options Weighted Average Remaining Contractual Term Exercisable
Options Exercisable, Weighted Average Exercise Price
Options Exercisable, Intrinsic Value
Weighted average fair value of options granted
Expected volatility, minimum
Expected volatility, maximum
Expected dividends
Risk free interest rate, minimum
Risk free interest rate, maximum
Upfront payment
Value of stock purchased
Development, regulatory and sales milestone payments
Upfront payment recorded as deferred revenue
Business combination amount transferred
Number of common stock shares
Common stock purchase price per share
Proceeds from issuance of stock
Reduction in research and development expenses
Support payments expenses
Proceeds from royalty received
Agreement expenses
Licensing revenue
Additional, cumulative sales milestone payments
Warrants outstanding
Warrant exercise price
Warrant term
Warrants expire date
Warrants exercised
Reimbursement value
Number of shares complaint alleges of common stock
Common stock price per share
Damages sought value by plaintiff
Litigation expense
Due from related party
Operating lease expiring date
Rent expense
2019
2020
2021
2022
2023
Thereafter
Total
Net operating loss carry-forward
Operating loss expiration year
Total net operating loss carry-forward
Net operating loss and deferred tax asset does not include nol's
New jersey state net operating loss carryovers
Income tax reconciliation description
Deferred tax assets
Income tax effective tax rate
Net cash amount received from sale of net operating losses and research and development tax credits
Current Federal
Deferred Federal
Current State and Local
Deferred State and Local
Change in valuation allowance
Income tax provision (benefit)
Net operating loss carryovers
Stock-based compensation
Research and development credits
Deferred revenue
Other deferred tax assets
Total deferred tax assets
Valuation allowance
Deferred tax asset, net of valuation allowance
Other deferred tax liabilities
Total deferred tax liabilities
Net deferred tax asset (liability)
US Federal statutory rate
State income tax, net of federal benefit
Permanent differences
Research and development credits
Income tax benefit from sale of New Jersey NOL carryovers
Change in valuation allowance
Tax Cuts and Jobs Act
Other
Income tax (provision) benefit
Number of common stock shares sold
Proceeds from sale of common shares
Sale of stock price per share
Sale of stock transaction during period, value
Number of common stock purchased
Warrants to purchase common stock
Warrant expiration term
Proceeds from registered direct offering, net of offering expenses
Common stock warrant liability, warrants exercisable at $1.50 through September 2024
Beginning balance
Issuance of warrants
Change in fair value
Ending Balance
Employee contributions, amount
Number of stock option grants
Exercise price
Reimbursement expense
Accounts Payable and Accrued Expenses settled with Common Stock.
Accredited Investor [Member].
Additional Shares [Member]
Advaxis public offering [Member]
Amgen Agreement [Member]
Amgen Inc [Member]
Aratana Agreement [Member]
Aratana Therapeutics [Member]
August September Convertible Promissory Notes [Member]
August - September 2012 Convertible Promissory Notes [Member]
Bridge notes [Member]
Co-Development and Commercialization Agreement [Member]
Collaboration Agreement [Member]
Common stock purchase warrant [Member]
Common Stock Warrant Liability [Member].
Consultant [Member]
Consultants [Member]
Consultants [Member]
Corporate Office & Manufacturing Facility Lease [Member]
Daniel J Oconnor [Member].
David J Mauro [Member]
December 22, 2017 [Member]
December two thousand fifteen [Member].
Director Stock Awards [Member]
Directors [Member]
Dr. Petit [Member]
Employee Stock Awards [Member]
Equity Warrants [Member].
Especificos Stendhal SA de CV [Member]
Executives [Member]
Exercise Price Range [Member]
Exercise Price Range [Member]
Exercise Price Range Six Point Zero [Member].
Exercise Price Range [Member]
Exercise Price Range [Member]
February 2018 [Member]
Finance [Axis].
First Amendment [Member]
Former Chairman [Member]
Former officer [Member]
401(k) Plan [Member]
Global BioPharma, Inc [Member]
Gregory T. Mayes [Member]
Health Care Specialist Investors [Member]
Interim Financial Report [Member]
January 1, 2018 [Member]
January 2018 [Member]
Junior Subordinated Convertible Promissory Note [Member]
Knight Therapeutics Inc [Member]
Knoll Capital Management LP [Member]
Liability warrants [Member]
Liability warrants one [Member]
Licensing Agreement [Member]
May 5, 2015 [Member]
May 2012 convertible debt financing [Member]
MedImmune Agreement [Member]
Merck Agreement [Member]
Mr. Moore [Member]
Non Executive Officer [Member]
November two thousand sixteen [Member].
Numoda Corporation [Member]
October 31, 2018 [Member]
October 2013 Through February 2018 [Member]
Treasury stock purchased to pay employee withholdings on equity awards.
Promissory Note Agreement [Member]
Promissory note and interest receivable [Member]
Promissory Note One [Member].
Reduced Federal Tax Rate[Member]
Registered Direct Offering [Member]
Restricted cash established with letter of credit agreement.
Restricted Stock Units RSU One [Member]
Robert GPetit [Member]
Sara M. Bonstein [Member]
Second Amendment [Member]
Knight TherapeuticsInc [Member]
Sellas Life Science Group [Member]
Shares Earned But Not Issued [Member].
Stendhal Agreement [Member]
Stock Bonus Award [Member].
Stock Purchase Agreement [Member].
Stock Purchase Agreements [Member]
Stock Split [Member]
Sublease Agreement [Member]
2011 Employee Stock Purchase Plan [Member]
2011 Omnibus Incentive Plan [Member]
2011 Employee Stock Purchase Plan [Member]
2015 Plan [Member].
2015 Voluntary Request To Purchase Of Equity [Member]
Two Thousand Fourteen Cash Bonus Equity [Member].
Two Thousand Fourteen Voluntary Request To Purchase Stock [Member].
Two Thousand Thirteen Base Salary Stock [Member].
Vendor and other [Member]
Warrants With Anti Dilution Provisions [Member].
Year One [Member]
Year Three [Member]
Year Two [Member]
Yenson [Member]
Executives and Employees [Member]
2011 Employee Stock Purchase Plan [Member]
Restricted Stock Units [Member]
Underwriting Agreement [Member]
Two Board Members [Member]
June 7, 2018 [Member]
Employee stock purchase plan expense.
October 2013 Through August 2018 [Member]
August 31, 2018 [Member]
Share-based compensation shares on net basis after employee payroll taxes.
Number of options outstanding, including both vested and non-vested options.
The weighted average grant-date fair value of options outstanding during the reporting period as calculated by applying the disclosed option pricing methodology.
Schedule of stock options table.
Schedule of stock options line items.
September 7, 2018 [Member]
2018 Employee Stock Purchase Plan [Member]
Tax withholdings paid on equity awards, shares.
Tax shares sold to pay for tax withholdings on equity awards, shares.
Stock Issued During Period Value Warrants Exercised.
Stock Issued During Period Shares Warrants Exercised.
Stock issued during period market sales.
Stock issued during period market sales, shares.
Common Stock Purchase Warrants and Warrant Liability [Text Block]
Collaboration Agreements [Policy Text Block]
Restricted Cash and Letter of Credit [Policy Text Block]
Treasury Stock [Policy Text Block]
Recently Adopted Accounting Standards Policy [Text Block]
Shares of common stock outstanding, percentage.
Fair value of equity purchases value.
Discount price percentage.
December 31, 2018 [Member]
October 2013 Through October 2018 [Member]
December 31, 2018 [Member]
Investments maturity description.
Finite lived patents expirations year.
Software Patents Gross.
Represents the number of warrants issued during the period.
Represents the number of warrants exercised during the period.
Represents the number of warrants expired during the period.
Class of Warrant or Right, Exercise Price of Warrants.
Issued weighted average exercise price.
Represents the exercise price of warrants exercised during the period.
Represents the exercise price of warrants expired during the period.
Weighted average remaining contractual period 1.
Weighted average remaining contractual period 2.
Derivative net liability aggregate intrinsic value.
Warrants One [Member]
Business Combination Upfront payment.
Support payments expenses.
Agreement expenses.
Additional, cumulative sales milestone payments.
Warrant term.
Weighted Average Remaining Contractual Life In Years, Ending.
Effective income tax rate reconciliation tax cuts and jobs act.
Total net operating loss carry-forward.
Operating Loss Carryforwards Expiration Year.
Proceeds from registered direct offering net of offering expenses.
Non Executive Directors [Member]
Reimbursement expense.
Licensing revenue.
Reimbursement value.
2015 Employee Stock Purchase Plan [Member]
Employee Stock Purchase Plan [Member]
Number of common stock purchased.
Net Operating Loss and DTA does not include NOL's.
Common stock warrant liability.
Number of warrants issued.
Warrant Liability [Member]
Schedule of changes in the fair value of warrant liabilities [Table Text Block]
Net proceeds of issuance of common stock and warrants.
Assets, Current
Assets
Liabilities, Current
Deferred Revenue, Noncurrent
Liabilities
Stockholders' Equity Attributable to Parent
Liabilities and Equity
Operating Expenses
Operating Income (Loss)
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest
Shares, Outstanding
Adjustments Related to Tax Withholding for Share-based Compensation
Gain (Loss) on Disposition of Property Plant Equipment
Accretion (Amortization) of Discounts and Premiums, Investments
Increase (Decrease) in Prepaid Expense and Other Assets
Increase (Decrease) in Income Taxes Receivable
Increase (Decrease) in Other Operating Assets
Increase (Decrease) in Deferred Revenue
Increase (Decrease) in Other Current Liabilities
Net Cash Provided by (Used in) Operating Activities
Payments to Acquire Investments
Payments to Acquire Property, Plant, and Equipment
Payments to Acquire Intangible Assets
Net Cash Provided by (Used in) Investing Activities
Payments Related to Tax Withholding for Share-based Compensation
Stock Bonus Award [Member]
Net Cash Provided by (Used in) Financing Activities
Cash, Period Increase (Decrease)
Cost Method Investments, Policy [Policy Text Block]
Property, Plant and Equipment, Policy [Policy Text Block]
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]
Income Tax, Policy [Policy Text Block]
Property, Plant and Equipment, Gross
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment
Finite-Lived Intangible Assets, Gross
Finite-Lived Intangible Assets, Accumulated Amortization
Finite-Lived Intangible Assets, Net
Warrants Expired
Commitments And Contingencies [Line Items]
Non Executive Employees [Member]
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberOne
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingInPeriodWeightedAverageGrantDateFairValue
WarrantTerm
Operating Leases, Future Minimum Payments Due, Next Twelve Months
Operating Leases, Future Minimum Payments, Due in Two Years
Operating Leases, Future Minimum Payments, Due in Three Years
Operating Leases, Future Minimum Payments, Due in Four Years
Operating Leases, Future Minimum Payments, Due in Five Years
Operating Leases, Future Minimum Payments, Due Thereafter
Operating Leases, Future Minimum Payments Due
Deferred Tax Assets, Deferred Income
Deferred Tax Assets, Valuation Allowance
Deferred Tax Assets, Net of Valuation Allowance
Deferred Tax Liabilities, Other
Deferred Tax Liabilities, Gross
Deferred Tax Assets, Net
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent